Project Grant R01AR083702

Award Date 5/3/24
Completion Date 4/30/29
Dollars Obligated $2.1M
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30332, USA
Similar Awards
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $295,247 will support the development of an innovative medical technology for localized and sustained antibiotic treatment of periprosthetic joint infection. Specifically, the awardee Reselute will design, develop, and validate a proof of concept for an orthopedic spacer implant with a novel porous medium capable of controlled antibiotic elution over 180 days. The implantable...
This $625,909 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) supports research and development of a hydrogel platform technology for delivering topical bacteriophage therapy to treat antibiotic-resistant wound infections. The award aims to develop innovative methods for sustained local delivery of bacteriophages - viruses that kill...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award to Reselute, Inc. provides $998,921 to develop a novel implantable orthopedic medical device and procedure to reduce recovery duration and infection risks associated with severe traumatic fractures of the long bones. The project aims to advance a 3D-printed, antibiotic-releasing intramedullary nail to improve upon current standard-of-care implants that are prone to...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), is providing $208,125 to the University of Connecticut Health Center to develop an intralesional drug delivery strategy for treating infected wounds. The key products and services to be delivered include: Characterization of in situ formed microneedle-like drug depots and...
This $821,426 Project Grant, awarded on January 16, 2025 by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under CFDA 93.286 - Discovery and Applied Research for Technological Innovations to Improve Human Health, is funding research to develop nanostructures that selectively target bacteria and create computational models to predict their activity and behavior. The key objectives are to: Use computer-guided design to create and test antimicrobial nanostructures against...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $873,546 to the University of Texas Health Science Center at Houston to develop an "oral micro-drug factory" using engineered Limosilactobacillus reuteri bacteria to secrete the anti-inflammatory cytokine interleukin-10 (IL-10) for treating periodontitis. The goal is to locally administer the...
This National Science Foundation (NSF) Division of Materials Research Project Grant, CFDA# 47.049 Mathematical and Physical Sciences, provides $400,000 in funding to The Trustees of the University of Pennsylvania to conduct collaborative research on developing novel hybrid metal-piezoelectric biomaterials for anti-infectious implantable medical devices. The key objective is to create advanced multifunctional biomaterial platforms that can effectively prevent biofilm formation and bacterial...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the CFDA program "Discovery and Applied Research for Technological Innovations to Improve Human Health", will support the development of a novel biomaterial delivery platform to spatiotemporally deliver bone morphogenetic proteins (BMP2 and BMP9) and promote regeneration of bone and articular cartilage following digit amputation. The $271,664 award, granted on May 10, 2025, will...
The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), awarded Matregenix Inc. a $976,000 project grant (Award ID R44DE035026) to develop MATRINOVA, an animal-free, amino acid-based biodegradable barrier membrane for guided bone regeneration in dental and craniomaxillofacial surgeries. The goal is to establish the efficacy and clinical significance of MATRINOVA, a bilayered membrane produced using...
This federal Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), aims to develop a novel therapeutic approach to improve angiogenesis and wound healing by delivering apoptotic neutrophils within a degradable hydrogel scaffold. The $172,700 award, effective August 20, 2024 through July 31, 2026, supports research to investigate the effects of the hydrogel-apoptotic neutrophil delivery on macrophage angiogenic signaling and its impact...

BACTERICIDAL HYDROGELS FOR BONE REPAIR - PROJECT SUMMARY BONE FRACTURES AND NON-UNION DEFECTS OFTEN REQUIRE SURGICAL INTERVENTION WHERE DEVICES ARE USED TO CORRECT THE DEFECT, AND 1-5% OF THESE PROCEDURES ARE COMPROMISED BY BACTERIAL INFECTION WITH ANNUAL HOSPITAL COSTS EXCEEDING $1.9B. CURRENT TREATMENTS ARE LIMITED TO SUSTAINED, HIGH SYSTEMIC DOSES OF ANTIBIOTICS AND SURGICAL DEBRIDEMENT OF AFFECTED TISSUE. THESE CORRECTIVE PROCEDURES SIGNIFICANTLY DRIVE HEALTHCARE COSTS AND HAVE SUB- OPTIMAL PATIENT OUTCOMES AS EFFECTIVE ANTIBIOTIC DOSES ARE DIFFICULT TO ATTAIN AT THE INFECTION SITE DUE TO THE PRESENCE OF A BIOFILM AND TOXICITY CONSIDERATIONS. FURTHERMORE, THE EMERGENCE OF ANTIBIOTIC-RESISTANT BACTERIA RAISES CONCERNS REGARDING THE EFFECTIVENESS OF CURRENT ANTIBIOTICS. THE OBJECTIVE OF THIS RENEWAL APPLICATION IS TO ENGINEER SYNTHETIC HYDROGELS CO-DELIVERING LYSOSTAPHIN AND ANTIBIOTICS TO ELIMINATE ESTABLISHED BACTERIAL INFECTIONS AND PROMOTE BONE REPAIR IN MURINE AND OVINE MODELS. OUR CENTRAL HYPOTHESIS IS THAT HYDROGEL-BASED DELIVERY OF LYSOSTAPHIN AND ANTIBIOTICS WILL SYNERGIZE TO ELIMINATE STAPHYLOCOCCAL INFECTIONS AND RESULT IN BONE HEALING IN MURINE AND OVINE MODELS OF IMPLANT-ASSOCIATED BONE INFECTION. THIS RESEARCH WILL ESTABLISH A LOCALIZED AND TRANSLATABLE STRATEGY TO EFFECTIVELY ELIMINATE ESTABLISHED BACTERIAL INFECTIONS TO SUPPORT BONE REPAIR. AIM 1. ENGINEER ANTIMICROBIAL HYDROGELS FOR THE TREATMENT OF INFECTED BONE FRACTURES IN MURINE MODELS OF BONE REPAIR. AIM 2. ENGINEER HYDROGELS CO-DELIVERING ANTIMICROBIAL AGENTS AND BMP-2 TO ELIMINATE ESTABLISHED BACTERIAL INFECTION AND REPAIR NON-HEALING SEGMENTAL BONE DEFECTS IN MICE. AIM 3. EVALUATE THE ABILITY OF ANTIMICROBIAL HYDROGELS TO MITIGATE BACTERIAL INFECTION AND SUPPORT BONE REPAIR IN A PLATE-STABILIZED OSTEOTOMY INFECTION MODEL IN SHEEP. THE PROPOSED RESEARCH IS INNOVATIVE BECAUSE IT FOCUSES ON ENGINEERING HYDROGELS THAT LOCALLY DELIVER ANTIMICROBIAL AGENTS TO ELIMINATE BACTERIAL INFECTION, MODULATE INFLAMMATION, AND SUPPORT BONE REPAIR. THIS NOVEL STRATEGY REPRESENTS A MORE EFFECTIVE AND SAFER ALTERNATIVE TO CURRENT SYSTEMIC ANTIBIOTIC REGIMENS AND ANTIBIOTIC- RELEASING BONE CEMENTS. THIS RESEARCH IS EXPECTED TO YIELD THE FOLLOWING SIGNIFICANT OUTCOMES. WE WILL ESTABLISH AN INJECTABLE ANTIMICROBIAL HYDROGEL FOR THE REPAIR OF INFECTED BONE FRACTURES AND NON-HEALING BONE DEFECTS. WE WILL ANALYZE THE EFFICACY, SAFETY, AND BIOLOGICAL MECHANISMS OF THESE BIOMATERIALS IN MURINE AND OVINE MODELS OF IMPLANT-ASSOCIATED BONE INFECTIONS.

Posted 5/3/24, 12:00 AM